New UK procedures for obtaining parallel trade licences kick in on 7 June
This article was originally published in SRA
The UK Medicines and Healthcare products Regulatory Agency has issued a best practice guidance document that parallel importers of medicinal products must conform to from 7 June when submitting their licensing submissions1.
You may also be interested in...
The UK’s deployment of COVID-19 vaccines has left vaccine manufacturers worried about emerging discussions on dosing strategies that may not be supported by authorized labeling or published clinical data.
Existing importers and manufacturers of certain medical devices can continue marketing their products for six months or until the Indian medtech regulator makes a final decision on their pending licensing applications.
Differences between how Australia and the EU define “central circulatory system” has resulted in different risk classification levels being assigned to some devices in the two jurisdictions.